Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 3,541 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infant Clear all
Terminated Phase 2 Interventional Results available

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

NCT04126031
View directory record Official record
Conditions
Gram-negative Bacterial Infection
Interventions
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Days to 88 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Two Regimens, With Healthy Male and Female Babies, Ages 3-6 Months Old, Using Various Assessments.

NCT03457857
View directory record Official record
Conditions
Microbiome
Interventions
Cleanser, Cleanser and Lotion
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
3 Months to 6 Months
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Skillman, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 23, 2026, 6:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

NCT05848687
View directory record Official record
Conditions
Lymphoblastic Leukemia
Interventions
Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib
Drug
Lead sponsor
Tanja Andrea Gruber
Other
Eligibility
Up to 1 Year
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Phase 4 Interventional

Telavancin Pharmacokinetics in Cystic Fibrosis Patients

NCT03172793
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Telavancin Injection
Drug
Lead sponsor
Joseph L. Kuti, PharmD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Hartford, Connecticut • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

NCT06551506
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Abrysvo, Beyfortus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
8
States / cities
Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Not applicable Interventional

Comparison of Phototherapy Using Neolight Skylife Versus Standardized Phototherapy for Hyperbilirubinemia in Newborns

NCT03599258
View directory record Official record
Conditions
Jaundice, Neonatal, Neonatal Hyperbilirubinemia, Neonatal Disorder
Interventions
Skylife, Standard Therapy
Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
0 Minutes to 7 Minutes
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 23, 2026, 6:31 AM EDT
Completed No phase listed Observational

Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity

NCT01780155
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Retinopathy of Prematurity, Prematurity, Pulmonary Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 23, 2026, 6:31 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The COLIC Study: Colonization of the Infant Gut With B. Infantis EVC001 to Reduce Symptoms of Colic

NCT05129384
View directory record Official record
Conditions
Infantile Colic
Interventions
B. infantis EVC001 or Lactose Placebo
Dietary Supplement
Lead sponsor
Evolve BioSystems, Inc.
Industry
Eligibility
14 Days to 42 Days
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 23, 2026, 6:31 AM EDT
Not listed Not applicable Interventional

Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates

NCT02445040
View directory record Official record
Conditions
Respiratory Distress Syndrome In Premature Infants
Interventions
Babylog VN500 in HFOV Mode
Device
Lead sponsor
Draeger Medical Systems, Inc.
Industry
Eligibility
23 Weeks to 30 Weeks
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
14
States / cities
Little Rock, Arkansas • San Diego, California • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 23, 2026, 6:31 AM EDT
Completed No phase listed Observational

Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus.

NCT03277768
View directory record Official record
Conditions
Premature Infant, Patent Ductus Arteriosus, Hemodynamic Instability
Interventions
Resonance Raman Spectroscopy (RRS)
Device
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
55 participants
Timeline
2015 – 2018
U.S. locations
2
States / cities
Gainesville, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 23, 2026, 6:31 AM EDT
Recruiting No phase listed Observational

Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)

NCT06669949
View directory record Official record
Conditions
Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
Interventions
no intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on Growth of an Extensively Hydrolyzed Formula Fed to Term

NCT00936637
View directory record Official record
Conditions
Growth
Interventions
Extensively hydrolyzed infant formula
Other
Lead sponsor
Perrigo Nutritionals
Industry
Eligibility
1 Day to 21 Days
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2009 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Not applicable Interventional

Iron Status and Myelination in Premature Infants

NCT00684697
View directory record Official record
Conditions
Neurodevelopmental Outcome
Interventions
iron
Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
Up to 32 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 23, 2026, 6:31 AM EDT
Withdrawn Phase 4 Interventional

Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass

NCT02122679
View directory record Official record
Conditions
Heart Defect, Congenital
Interventions
Tranexamic Acid, placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 6 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 23, 2026, 6:31 AM EDT
Not listed No phase listed Observational

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

NCT06539169
View directory record Official record
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Not applicable Interventional

Post-Gastric Bypass Hypoglycemia

NCT01933490
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia
Interventions
high carbohydrate test meal, high carbohydrate test meal after pre-treatment with rapid acting aspart insulin, high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal
Other
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00104520
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2011 · Synced Oct 23, 2026, 6:31 AM EDT
Completed No phase listed Observational

Changes in Lung Function Based on Differences in Spirometry Equipment Used in Children With Cystic Fibrosis

NCT01343524
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
4 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

NCT06143046
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
0 Years to 40 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
22
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 23, 2026, 6:31 AM EDT
Enrolling by invitation Not applicable Interventional

Families Moving Forward Bridges: An Early Intervention for Infants and Toddlers With PAE With or At-risk for FASD

NCT06935461
View directory record Official record
Conditions
Prenatal Alcohol Exposure, Fetal Alcohol Spectrum Disorders
Interventions
Families Moving Forward Bridges
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
6 Months and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Shoreline, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 23, 2026, 6:31 AM EDT
Terminated Not applicable Interventional

Infantile Colic: Study of the Efficacy of Lactobacillus GG (ATCC 53103) Plus Chamomile in Breastfeeding Infants

NCT03477669
View directory record Official record
Conditions
Infantile Colic
Interventions
chamomile/probiotic arm, Placebo of chamomile/probiotic arm
Dietary Supplement
Lead sponsor
University of Nebraska
Other
Eligibility
3 Weeks to 16 Weeks
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia

NCT01022580
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Infasurf surfactant (ONY, Inc.), Sham (No Treatment)
Drug
Lead sponsor
Roberta Ballard
Other
Eligibility
7 Days to 14 Days
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Little Rock, Arkansas • Berkeley, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Phase 1Phase 2 Interventional

Feasibility of Mid-frequency Ventilation in Newborns With RDS: Randomized Crossover Pilot Trial

NCT01242462
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Conventional Pressure Controlled SIMV, Mid-frequency Ventilation
Procedure · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Hour to 7 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 23, 2026, 6:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Term Infants Fed Milk-Based Infant Formula

NCT04529759
View directory record Official record
Conditions
Tolerance
Interventions
Control Infant Formula, Experimental Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 14 Days
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
6
States / cities
Tucson, Arizona • Tampa, Florida • Owensboro, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 23, 2026, 6:31 AM EDT